Trial
NCT01822756
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Incyte Corporation
Collaborators
—
Condition
Solid Tumors
Intervention
ruxolitinib
Why stopped
Dose escalation ended after Cohort B1, RUX 10 mg BID - GCSF in October 2014.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-02-12